Stellanova Therapeutics Inc.

Stellanova Therapeutics Inc. is a US-based biotechnology company focused on developing innovative cancer treatments through targeted therapies, aimed at improving patient outcomes and advancing oncology research. Founded in 2019, Stellanova Therapeutics Inc. operates from Houston, US.

The firm specializes in advancing cancer therapies and has raised USD 15. 5 mn in a Series A funding round led by Sporos Bioventures on June 3, 2021. The company's CEO is Emmanuelle Schuler, who is committed to driving forward its mission in oncology. Stellanova Therapeutics Inc.

develops innovative cancer treatments through a strategic portfolio approach focused on targeted therapies in oncology. Its partnerships include equity interests in biopharma entities like Tvardi Therapeutics and Asylia Therapeutics, collaborating to create therapeutic solutions for various types of cancer. The clientele mainly consists of healthcare providers, oncology specialists, and research institutions involved in clinical trials. The company operates in North America, Europe, and parts of Asia.

Stellanova Therapeutics Inc. generates revenue through strategic partnerships and equity stakes in its biopharma portfolio, encompassing collaborative development agreements. Revenue is primarily derived from milestone payments related to successful clinical trials, licensing agreements, and royalties from marketed products, reflecting the firm's commitment to maintaining long-term partnerships in the oncology sector. Following the Series A funding of USD 15.

5 mn in June 2021, Stellanova Therapeutics Inc. plans to advance its lead antibody asset into human clinical trials for oncology. The funding will also support the establishment of its discovery platform and the expansion of its team. These initiatives aim to enhance the company's footprint in the oncology market and facilitate the development of new therapeutic products.